<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26093979</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.</ArticleTitle><Pagination><StartPage>889</StartPage><EndPage>897</EndPage><MedlinePgn>889-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(15)00093-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(15)00093-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Supplementary immunisation activities with oral poliovirus vaccines (OPVs) are usually separated by 4 week intervals; however, shorter intervals have been used in security-compromised areas and for rapid outbreak responses. We assessed the immunogenicity of monovalent type-1 oral poliovirus vaccine (mOPV1) given at shorter than usual intervals in Karachi, Pakistan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a multicentre, randomised, controlled, four-arm, open-label, non-inferiority trial done at five primary health-care centres in low-income communities in and around Karachi, Pakistan. Eligible participants were healthy newborn babies with a birthweight of at least 2&#xb7;5 kg, for whom informed consent was provided by their parent or guardian, and lived less than 30 km from the study clinic. After receiving a birth dose of trivalent OPV, we enrolled and randomly assigned newborn babies (1:1:1:1) to receive two doses of mOPV1 with an interval of 1 week (mOPV1-1 week), 2 weeks (mOPV1-2 weeks), or 4 weeks (mOPV1-4 weeks) between doses, or two doses of bivalent OPV (bOPV) with an interval of 4 weeks between doses (bOPV-4 weeks). We gave the first study dose of OPV at age 6 weeks. We did the randomisation with a centrally generated, computerised allocation sequence with blocks of 16; participants' families and study physicians could not feasibly be masked to the allocations. Trial participants were excluded from local supplementary immunisation activities during the study period. The primary outcome was non-inferiority (within a 20% margin) between groups in seroconversion to type-1 poliovirus. The primary and safety analyses were done in the per-protocol population of infants who received all three doses of vaccine. This trial is registered with ClinicalTrials.gov, number NCT01586572, and is closed to new participants.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between March 1, 2012, and May 31, 2013, we enrolled 1009 newborn babies, and randomly assigned 829 (82%) to treatment. 554 (67%) of the 829 babies were included in the per-protocol analysis. Proportions of seroconversion to type-1 poliovirus were 107/135 (79%, 95% CI 72&#xb7;4-86&#xb7;1) with mOPV1-1 week, 108/135 (80%, 73&#xb7;2-86&#xb7;8) with mOPV1-2 weeks, 129/148 (87%, 80&#xb7;9-92&#xb7;0) with mOPV1-4 weeks, and 107/136 (79%, 71&#xb7;8-85&#xb7;6) with bOPV-4 weeks. Non-inferiority was shown between groups and no significant differences were noted. Ten participants died during the trial. Seven of these deaths occurred during the lead-in period before randomisation (two from diarrhoea, five from unknown causes). Three infants died from sepsis after random assignment. No deaths were attributed to the procedures or vaccines. Additionally, we noted no events of vaccine-associated paralysis.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We identified no significant differences in responses to mOPV1 given with shorter intervals between doses than with the standard 4 week intervals. The short-interval strategy could be particularly beneficial when temporary windows of opportunity for safe access can be granted in areas of conflict--eg, during cease-fire periods. In such situations, we recommend shortening the interval between OPV doses to 7 days.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">World Health Organization.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mir</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quadri</LastName><ForeName>Farheen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Research, Policy and Product Development, WHO, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Imran</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatti</LastName><ForeName>Zaid</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Asia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehman</LastName><ForeName>Najeeb Ur</ForeName><Initials>NU</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durry</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Polio Eradication Initiative, WHO, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salama</LastName><ForeName>Maha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research, Policy and Product Development, WHO, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Population Immunity Laboratory Polio and Picornavirus Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Population Immunity Laboratory Polio and Picornavirus Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Research, Policy and Product Development, WHO, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaidi</LastName><ForeName>Anita K M</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan. Electronic address: anita.zaidi@aku.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01586572</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>D43 TW007585</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 D43 TW007585-01</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2015 Aug;15(8):864-5. doi: 10.1016/S1473-3099(15)00092-4</RefSource><PMID Version="1">26093978</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010154" MajorTopicYN="N" Type="Geographic">Pakistan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Declaration of interests</b>. We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26093979</ArticleId><ArticleId IdType="mid">NIHMS726683</ArticleId><ArticleId IdType="pmc">PMC4644524</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(15)00093-6</ArticleId><ArticleId IdType="pii">S1473-3099(15)00093-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robertson SE, Chan C, Kim-Farley R, Ward N. Worldwide status of poliomyelitis in 1986, 1987 and 1988, and plans for its global eradication by the year 2000. World Health Stat Q. 1990;43:80&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375131</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Wild poliovirus 2009&#x2013;14.   http://www.polioeradication.org/Portals/0/Document/Data&amp;Monitoring/Wild_poliovirus_list_2009_2014_29JUL.pdf (accessed Sept 16, 2014)</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001;50:222&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11300627</ArticleId></ArticleIdList></Reference><Reference><Citation>Global polio eradication initiative. Wild poliovirus (WPV) case breakdown by country. 2013  http://www.polioeradication.org/dataandmonitoring/poliothisweek.aspx (accessed Sept 16, 2014)</Citation></Reference><Reference><Citation>Boone J.  Taliban leader bans polio vaccinations in protest at drone strikes. The Guardian; London: Jun 26, 2012.   http://www.theguardian.com/world/2012/jun/26/taliban-bans-polio-vaccinations (accessed Aug 26, 2014)</Citation></Reference><Reference><Citation>WHO. Statement on the meeting of the International Health Regulations Emergency Committee concerning the international spread of wild poliovirus. 2014  who.int/mediacentre/news/statements/2014/polio-20140505/en/ (accessed May 5, 2014)</Citation></Reference><Reference><Citation>Baicus A. History of polio vaccination. World J Virol. 2012;1:108&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782271</ArticleId><ArticleId IdType="pubmed">24175215</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec. 2014;89:73&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24707513</ArticleId></ArticleIdList></Reference><Reference><Citation>Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull World Health Organ. 1985;63:1151&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2536468</ArticleId><ArticleId IdType="pubmed">3914926</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin AB. Oral, live poliovirus vaccine for elimination of poliomyelitis. Arch Intern Med. 1960;106:5&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14440554</ArticleId></ArticleIdList></Reference><Reference><Citation>Salisbury D. Immunisation policies and programmes in Europe. Biologicals. 1994;22:313&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">7779354</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine&#x2014; live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th. London: WB Saunders; 2013. pp. 598&#x2013;645.</Citation></Reference><Reference><Citation>WHO. WHO vaccine-preventable diseases: monitoring system. 2014 global summary.  http://apps.who.int/immunization_monitoring/globalsummary(accessed May 21, 2015)</Citation></Reference><Reference><Citation>Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci. 1995;754:289&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">7625665</ArticleId></ArticleIdList></Reference><Reference><Citation>Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. J Infect Dis. 1997;175(suppl 1):S215&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203720</ArticleId></ArticleIdList></Reference><Reference><Citation>el-Sayed N, el-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med. 2008;359:1655&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923170</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication&#x2013;Afghanistan and Pakistan, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:268&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">20224544</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming MS, Jaiteh KO, Otten MW, Jr, et al. Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease. II. Clinical efficacy of trivalent oral polio vaccine. Am J Epidemiol. 1992;135:393&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">1550091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale JH, Doraisingham M, Kanagaratnam K, Leong KW, Monteiro ES. Large-scale use of Sabin type 2 attenuated poliovirus vaccine in Singapore during a type 1 poliomyelitis epidemic. Br Med J. 1959;1:1541&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1993778</ArticleId><ArticleId IdType="pubmed">13662613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkenazi A, Melnick JL. Heterotypic antibody response after feeding of monovalent attenuated live poliovaccine. N Engl J Med. 1962;267:1228&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">13965178</ArticleId></ArticleIdList></Reference><Reference><Citation>Global polio eradication initiative. Polio eradication &amp; endgame strategic plan 2013&#x2013;18.   http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf (Oct 26, 2013)</Citation></Reference><Reference><Citation>Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and The Gambia. World Health Organization collaborative study group on oral poliovirus vaccine. J Infect Dis. 1995;171:1097&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">7751683</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent du Chatelet I, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine. 2003;21:1710&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639494</ArticleId></ArticleIdList></Reference><Reference><Citation>Isomura S, Mubina A, Dure-Samin A, et al. Virological and serological studies on poliomyelitis in Karachi, Pakistan. I. Outbreaks in 1990&#x2013;91. Acta Paediatr Jpn. 1993;35:382&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">8256620</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder N, Handsher R, Fruman O, et al. Effect of maternal immunization with oral poliovirus vaccine on neonatal immunity. Pediatr Infect Dis J. 1994;13:959&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845748</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin-Murphy M, Tan KL, Lim GN, Quek JH, Ishak B, Phoon MC. Poliovirus neutralising antibody in infants and cord blood. Ann Acad Med Singapore. 1993;22:281&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8396883</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming MS, Linkins RW, Jaiteh KO, Hull HF. The clinical efficacy of trivalent oral polio vaccine in The Gambia by season of vaccine administration. J Infect Dis. 1997;175(suppl 1):S254&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell SF. Seasonal variation in host susceptibility and cycles of certain infectious diseases. Emerg Infect Dis. 2001;7:369&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631809</ArticleId><ArticleId IdType="pubmed">11384511</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC, Jafari H, Bahl S, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205:1554&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">22448007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA. 1960;173:1521&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">14440553</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman RA, Holguin AH, Gelfand HM. Oral poliovirus vaccination in children: a study suggesting enterovirus interference. Pediatrics. 1964;33:526&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14166532</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado YA, Pena-Cruz V, de la Luz Sanchez M, et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis. 1997;175:545&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110245</ArticleId><ArticleId IdType="pubmed">9041324</ArticleId></ArticleIdList></Reference><Reference><Citation>Myaux JA, Unicomb L, Besser RE, et al. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J. 1996;15:204&#x2013;09.</Citation><ArticleIdList><ArticleId IdType="pubmed">8852907</ArticleId></ArticleIdList></Reference><Reference><Citation>Posey DL, Linkins RW, Oliveria MJ, Monteiro D, Patriarca PA. The effect of diarrhea on oral poliovirus vaccine failure in Brazil. J Infect Dis. 1997;175(suppl 1):S258&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203726</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368:416&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Domingo J, Cantarino MV, Torrenti JM, et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29:148&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">19927040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallet E, Belohradsky BH, Lagos R, et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine. 2004;22:1343&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">15063556</ArticleId></ArticleIdList></Reference><Reference><Citation>Herremans TM, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol. 1999;162:5011&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202050</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras G, Dimock K, Furesz J, et al. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals. 1992;20:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">1319179</ArticleId></ArticleIdList></Reference><Reference><Citation>John TJ. Anomalous observations on IPV and OPV vaccination. Dev Biol (Basel) 2001;105:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11763328</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlov DN, Van Zyl WB, Van Heerden J, Grabow WO, Ehlers MM. Prevalence of vaccine-derived polioviruses in sewage and river water in South Africa. Water Res. 2005;39:3309&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15996707</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>